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Exosomes are a unique subpopulation of naturally occurring extracellular vesicles which are smaller intracellular
membrane nanoparticle vesicles. Exosomes have proven to be excellent nanocarriers for carrying lipids, proteins,
mRNAs, non-coding RNAs, and DNAs, and disseminating long-distance intercellular communications in various
biological processes. Among various cell-line or biological fluid derived exosomes, milk exosomes are abundant
in nature and exhibit many nanocarrier characteristics favorable for theranostic applications. To be an effective
delivery carrier for their clinical translation, exosomes must inbuilt loading, release, targeting, and imaging/
tracking characteristics. Considering the unmet gaps of milk exosomes in theranostic technology it is essential to
focus the current review on drug delivery and imaging applications. This review delineates the efficiency of
exosomes to load therapeutic or imaging agents and their successful delivery approaches. It is emphasized on
possible modifications of exosomes towards increasing the stability and delivery of agents. This article also
summarizes the specific applications and the process of developing milk exosomes as a future pharmaceutical
drug delivery vehicle.

1. Introduction
Extracellular vesicles (EVs) are a class of secreted biomolecular lipidbilayer nanostructures. The prime function of EVs is to transport various
types of cellular components such as proteins, lipids, mRNAs, micro
RNAs, receptors, and effector molecules to the recipient cells (Fig. 1).
The EVs were first discovered over three decades ago. Their connection
to human metabolism, immunology, and physiology is widely estab
lished. Based on the process of intracellular origin, excretion, biogenesis,
size, and their function, EVs have been classified into three categories
such as exosomes, microvesicles, and apoptotic bodies. Exosomes (Exo)
are a unique subpopulation of nanosized spherical membrane vesicles
with particle size between 30 and 150 nm (Fig. 1A and B). This term was
invented by Dr. Rose Johnstone while identifying the biologic process
with maturing reticulocytes [1–3]. His team observed that the cytoplasm
of reticulocytes is comprised of large sacs filled with small
membrane-enclosed structures of uniform size which are extruded

outside the cells. Exosomes are often created by multivesicular bodies
which are exported out via fusion with the cell plasma membrane
(Figure 1A). Since the process of secretion is opposed to endocytosis,
these extruded vesicles were named as “exosomes”. Whereas cellular
membrane vesicles in a size range between 50 nm and 1 μm are
considered as “microvesicles” (Fig. 1A) [11]. The biogenesis of micro
vesicles is distinct from exosomes, which occurs due to a straightforward
outward blossoming and breaking up of the plasma membrane. Since
there is some overlap in the certain size ranges of exosomes and
microvesicles, it is important to distinguish based on their mechanism of
biogenesis. On the other hand, both exosomes and microvesicles consist
of a variety of fragments from the parent cells, including microRNAs,
messenger RNAs, lipids, and proteins. Apoptotic bodies often shed
cellular contents (deoxyribonucleic acid, ribonucleic acid, and histone
proteins) up to 5 μm larger particles (Fig. 1A). Variations among these
extracellular vesicles (exosomes, microvesicles, and apoptotic bodies)
can be visualized through transmission electron microscopic images [4].
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A more detailed explanation of the biogenesis and constitution of exo
somes, microvesicles, apoptotic bodies, and other types of extracellular
vesicles (components) can be referred to the latest documents [5].
Among all types of EVs, exosomes have received much attention due
to their therapeutic, theranostic, and diagnostic applications. EVs are
released by numerous cells and their presence of abundance can be seen
in several body fluids, such as plasma, urine, saliva, bronchoalveolar
lavage fluid, synovial fluids, amniotic fluid, malignant ascites, etc. Wang
et al. [6] documented a broad view of statistical analysis of the state of
exosomal research based on 4960 publications (from all over the world,
25 countries: USA-highest and Iran-lowest). The co-occurrence analysis
mapping confirms that in vitro and in vivo studies were commonly
documented, but “exosomal mechanism related research” is extensively
reported. A comprehensive survey on the role of exosomes and other
extracellular vehicles as diagnostic and therapeutic modalities was
delineated by the number of publications, patents, intellectual property,
and government funding [7]. Other global scientific trends on exosomal
research (2007–2016, from 1850 publications) have been divided into
three major clusters: “tumor related”, “stem cell”, and “drug resistance”
[8]. It was also observed that “Michigan Cancer Foundation-7” was
highly studied due to a breast cancer cell line. The overall publication
trends demonstrated that exosomes were highly applied for cancer
detection applications [9]. Based on extensive utility in several fields of
medicine several US companies are focused on producing and imple
menting exosomal research including, Aethlon Medical, Inc., Exosome
Diagnostics Inc., NanoSomix Inc., ThermoFisher Scientific Inc., YMIR
Genomics LLC., and System Biosciences Inc.

medical sciences is low. Milk is a primary source of postnatal nutrition
for all newborn mammals [12]. Breast milk feeding supports the
newborn with the growth and development of intestinal microbiota and
immunity [13]. Literature covers various investigations on milk exo
somes, for their isolation processes, drug delivery, imaging, and thera
peutic applications. Table 1, summarizes several review articles
comprised of milk exosomes that are specific to i) metabolic regulation,
ii) association with human diseases, iii) abundance of microRNAs and
other biological molecules, iv) biological influence in infant and adults,
and v) isolation methods. A detailed breakdown of individual review
reports and their major focus is presented (Table 1). A portion of the
article also covered the anticancer drug delivery aspect using milk
exosomes, but this article used very limited examples. Altogether, there
is no focused review article that is specifically devoted to milk exosomes,
for isolation protocols, characterization, their significance in delivery of
small molecules, imaging agents, and biomolecules, and developing as
hybrid/engineered nanocarrier system for possible therapeutic impli
cations. Therefore, this article aimed to describe conclusive information
towards developing milk exosomes as unique nanocarriers for both
imaging and therapeutic application. The additional section also covers
the possible future directions and translational potential of this nano
carrier system.
3. Milk exosome isolation
A detailed overview of the isolation methods of exosomes from
various resources has been well documented in the literature [28]. Ul
tracentrifugation,
size
exclusion
chromatography,
micro-/
nano-filtration, immunological, and polymer-based precipitation are
some of the widely used methods to separate or isolate exosomes. Exo
somal contents (proteins, lipids, and luminal molecules) and population
size differ between each type of isolation method and the source of
exosomes. Few articles have been specifically devoted to educate about
the use of various types of isolation methods, their suitability, possible
advantages, and disadvantages [29,30]. Various commercial isolation
reagent kits are also available for quick isolation of exosomes using
various principles. Among them, ThermoFisher, Sigma, FUJIFILM Wako
Pure Chemical Corporation, IZON, Qiagen, Biocompare, System Bio
sciences, Takara Bio, Miltenyi Biotec, Nano View Biosciences, BioVision
Inc., BioCat GmbH, etc are well-known resources. However, many of
these kits are specifically applied to cell culture and human biological
fluid-derived exosomes. Therefore, in this section, the commonly
applied isolation methods are documented for milk exosomes.
There is no one standard method that is followed for the isolation of
exosomes from milk. Successful isolation of milk-derived exosomes itself

2. Milk exosomes
The PubMed search criteria in the title and abstract with the keyword
“exosome(s)” led over 15,780 articles (Data accessed on Oct 15, 2020,
Fig. 2A). This information suggests that exosomes are highly studied in
cancer and drug delivery. The PubMed search revealed that scientific
peer-reviewed publications started in early 1966 [1966 (1), 1984 (1),
1986 (1), and 1996 (1)]. The first milk-derived exosome-based research
was published in 2007 [10]. There are about 256 publications on milk
exosomes (Fig. 2B) in general out of which 57, 51/19, 4, 2, 12, and 1
reports belong to human breast milk, bovine/cow milk, goat milk, camel
milk, porcine milk, and horse milk, respectively (Fig. 2C) [11]. These
sources can produce liters of milk per day which can yield huge amounts
of exosomes compared to cell lines or other biological fluid-based exo
somes. These exosomes produce a uniform particle size of ~100 nm
(Fig. 2D) which is highly recommended for therapeutic applications.
However, up to date, the use of milk exosomes in research and

Fig. 1. A) A schematic representation of cellular vesicle production (exosomes, microvesicles, and apoptotic bodies) from cells including milk. Distinct variation in
the biogenesis and excretion from cell to yield different size range excretes. B) An illustration of exosome structure with rich source for protein, nucleic acid, enzyme,
lipids, and cargos.
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Fig. 2. A-C) Peer-reviewed scientific
reports and review articles covering
various aspects of exosomes recorded
using PubMed website https://www.
ncbi.nlm.nih.gov/.
All
data
was
retrieved on Oct 12, 2020. A) Number of
articles found that are published in the
literature in each year since 2001 to
2020. B) Number of articles noticed in
each year with key word of “Milk” and
exosomes, C) Articles found in search
with key words of “human milk” and
exosome, “bovine/cow milk” and exo
some, “horse milk” and exosome,
“camel milk” and exosome, “goat milk”
and exosome, and “porcine milk” and
exosome. D) An example of size distri
bution of bovine milk exosomes derived
from fat free Horizon organic milk using
acetic acid precipitation method. It
shows a uniform particle size of ~100
nm.

turns out to be a valuable area of research. There is an unmet need to
develop a consistent and reproducible exosome isolation method.
Isolation or separation of non-vesicular entities from exosomes is not
completely accomplished by simple protocols (centrifugation or com
mercial kits or polymer-based methods). In this regard, the International
Society for Extracellular Vesicles (ISEV) established appropriate pro
tocols, recommendations, and requirements for achieving highly puri
fied exosomes with intact morphology and components [31]. These
standards are often updated with numerous amendments.
Table 2 presents the commonly used techniques to isolate the milk
exosomes and their principles, advantages, disadvantages, yield, and
purity [27,32,33]. However, it is important to note that milk-derived
exosomes are inexpensive unlike other cell or biological fluids, thus
ultracentrifugation is highly preferred [34,35]. All other methods are
associated with high cost.
The differential ultracentrifugation method is highly suitable for
isolating exosomes from bovine and human milk. This method provides
the purest form of exosomes with highly intact bio-factories. For
example, bovine milk exosomes can be produced with this method by
various groups within the range of 30–150 nm [14,35–39]. Ultracen
trifugation (UC) is also employed to obtain milk-derived exosomes from
different species such as goat (122 nm) [40], horse (~100 nm) [41],
camel (30–100 nm) [42], and porcine (50–100 nm) [43]. Both yak milk
and cow milk-derived exosomes have a similar particle size distribution
of 131.1 ± 53.25 nm and 131.5 ± 52.39 nm, respectively in dynamic
light scattering-based measurements [44].
Recent evidences support that acidification is helpful in the quick
isolation of milk exosomes [45,46]. Acidification with hydrochloric acid
(HCl) and acetic acid (AA) yields exosomes with size ~124 nm and 132
nm, respectively which are close to 126 nm exosomes isolated by UC
method [45]. On the other hand, the particle concentration of exosomes
was obtained as 2.6 × 109, 1.7 × 109, and 4.8 × 108 particles/mL with
AA, HCl, and UC methods, respectively. In addition, the morphology and
concentration of protein are very similar to UC derived exosomes. This
suggests that the acid treatments yielded significantly higher amounts of
exosomes relative to UC. Another comparative method of exosomes

isolated from raw milk using ultracentrifugation (70,000 rcf) and iso
electric precipitation (IP) (adjusting with pH of milk to 4.6 with HCl)
resulted in a very similar size population of 120 nm [46]. Additionally,
IP method resulted in a higher number of exosomes (1.7 × 109 parti
cles/ml) compared to ultracentrifugation (4.8 × 108 particles/ml).
However, the ultracentrifugation method provided smooth surface
constituted exosomes. Horse milk exosomes with 40–100 nm size range
population were obtained for the first time by Sedykh et al. [41].
Further, its purification with gel filtration produced exosomes contain
ing small number of major proteins.
Yamada et al. [35], reported a comparative study for isolating exo
somes from bovine milk. Their study concludes that ultracentrifugation
with ExoQuick precipitation is a useful method for rapid isolation and
high exosome recovery. The ultracentrifugation with a density gradient
centrifugation method allows for an efficient and purified form of exo
somes with native morphology. These methods are superior compared to
ExoQuick precipitation alone. A recent systematic comparison of
methods was implemented for the extraction of exosomes isolated from
bovine and human milk [34]. In support of this study, a recent investi
gation with three independent isolation methods suggests that ExoQuick
precipitation method is highly suited for milk exosomal isolation than
ultracentrifugation [34].
Vaswani et al. [47], validated a superior isolation method for the
extraction of extracellular vesicles (30–200 nm) from milk using size
exclusion chromatography column (qEV) over ultracentrifugation. The
12–16 fractions of these vesicles that were tested provide over 1 × 108
particles/mL with qEV while ultracentrifugation method resulted in
only ~2.2 × 08 particles/mL. Bovine milk exosomes (176.9 nm) yield
~12 × 1013 particles/mL which is significantly higher than human milk
exosomes (188.8 nm, ~4.0 × 1012 particles/mL) [48]. A sequential
centrifugation along with the size exclusion chromatography isolation
method was used to achieve exosomes from bovine and human milk
[49]. This study confirms that the concentration of exosomes is higher in
bovine milk than human milk, i.e., 1.34 × 1012 to 1.50 × 1012 (bovine
milk, centrifugation) compared to 4.88 × 1011 to 1.00 × 1012 (human
milk, centrifugation). These studies support the feasibility of scalable
2481
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Table 1
Peer-reviewed research review articles and book chapters discussing milkderived exosomes and their possible in in vitro, in vivo, biological, and medi
cal applications.
Title of the article

Various topics covered under each article

MicroRNA Milk Exosomes: From
Cellular Regulator to Genomic
Marker [14]
Milk-Derived Exosomes and Metabolic
Regulation [15]

This review documented the possible
applications of exosomes in metabolism
and health, and genomic markers.
A detailed review of endogenous
exosomes (exosome cargos and cell-tocell communication), bioavailability and
distribution of exosomes and their cargos,
and interactions of milk exosomes with
the gut microbiome. This study also
documents information on phenotypes of
dietary depletion of exosomes and cargo,
and their influence on immune system.
This article reports a cumulative study of
exosomes (including breast milk) serving
as biomarkers for disease diagnosis and
prognosis. This article also highlights the
significance of exosomes for possible
translational medicine.
This review brings awareness on milk
exosomes which may transfer dairy cow
mammary epithelial cells-derived
miRNA-29s and fat mass and obesityassociated mRNA to the milk consumers.
The amplifying fat mass and obesityassociated gene expression which may
introduce obesity, T2DM, prostate and
breast cancer, and neurodegenerative
diseases.
This work cites a number of works
associated to i) exosomes in health and
disease, ii) exosomes in maternal health,
and iii) proteomics and micronutrient
profiling of human breast milk exosomes.
This study confirms the evidence that
noncanonical pathways dietary
microRNAs may alter gene expression at
low concentrations. Breastfed infants
have a higher Mental Developmental
Index, Psychomotor Development Index,
and Preschool Language Scale-3 scores
compared to those fed various formulas.
Milk exosomes often contain miRNA-21
which involves enhancing mTORC1driven metabolic processes. Therefore,
breastfeeding is ideal for infants
permitting suitable postnatal growth and
species-specific metabolic programming,
However, high cow’s milk consumption
may promote such signaling and its
driven diseases of civilization.
This review offers an analysis of a number
of articles documenting milk
consumption, milk-associated miRNA
hallmark in western diet, and possible
risk developing chronic diseases.
This article cites a number of therapeutic
benefits of breast milk-derived exosomes
and their remedial effect in the
gastrointestinal disease necrotizing
enterocolitis.
This work delineates miRNAs of breast
milk-derived exosomes and their
important roles in infants’ development,
maturation, and potential biological
effects. This work also extends possible
implications in pharmacological and
pharma-nutritional consequences.
This review article gives an overview of
miRNAs and gene expression via milkderived miRNAs to consumers. Further,
this article also discusses how the
commercial interest may further

Exosome: An Emerging Source of
Biomarkers for Human Diseases [16]

Milk: an epigenetic amplifier of FTOmediated transcription? Implications
for Western diseases [17]

"Exosomics"-A Review of Biophysics,
Biology and Biochemistry of
Exosomes With a Focus on Human
Breast Milk [18]
Biological Activities of Extracellular
Vesicles and Their Cargos from
Bovine and Human Milk in Humans
and Implications for Infants [19]

Milk is not just food but most likely a
genetic transfection system activating
mTORC1 signaling for postnatal
growth [20]

Exosomes of pasteurized milk: potential
pathogens of Western diseases [21]

The Therapeutic Potential of Breast
Milk-Derived Extracellular Vesicles
[22]
Breast milk microRNAs harsh journey
towards potential effects in infant
development and maturation. Lipid
encapsulation can help [23]

Milk’s Role as an Epigenetic Regulator
in Health and Disease [24]

Table 1 (continued )
Title of the article

Milk Exosomes: Isolation, Biochemistry,
Morphology, and Perspectives of Use
[25]
Milk Exosomes: Perspective Agents for
Anticancer Drug Delivery [26]

Milk exosomes: A biogenic nanocarrier
for small molecules and
macromolecules to combat cancer
[27]

Various topics covered under each article
influence the epigenetic miRNA burden
for the milk consumer.
This book chapter presents i) methods of
exosome isolation, purification, and
analysis, ii) biochemistry of milk
exosomes, and iii) brief overview of its
use.
Extensively discusses bioactive
compounds of milk exosomes: proteins,
nucleic acids, and lipids in milk
exosomes. It also provides drug delivery
applications of milk exosomes in cancer
therapy.
This article emphasized the various
isolation methods and the evaluation of
physicochemical, biodistribution, and
delivery characteristics of exosomes to
combat cancer.

isolation of exosomes from the large volumes of milk. Recently, Kaddour
et al. [50], developed a high-resolution size guided turbidimetry based
particle purification liquid chromatography for achieving superior
quality exosomes from various types of resources including cow milk.
Ultracentrifugation uses 100,000–200,000 g (1–20 h) for successful
separation/depletion of exosomes from a larger volume often for in
dustrial/commercial usage. This method is highly time-consuming and
difficult to standardize. A new solid-phase extraction method based on
molecular imprinted polyester capillary-channeled polymer fiber sta
tionary phase in a spin-down tip format is developed to isolate the
exosomal population from aqueous medium, urine, milk, and serum
[51]. This method can recover the exosomal population fraction from
the aqueous, urine, and milk samples ~1.5 × 1010 and ~1.3–1.4 × 109
at 1/100 and 1/1000 dilutions, respectively. As a result, no significant
difference was noticed among all types of sources in achieving exosomal
population. This further motivated to develop polycarbonate or
nitrocellulose-based membrane filters to isolate cells and large EVs in
biological samples by combining with ultracentrifugation [52]. Such
protocols are highly implemented to generate exosomes from serum or
media and biological fluids.
It is imperative to characterize the isolated milk exosomes for their
successful use in research, development, and clinical applications.
Physicochemical properties of exosomes play an important role in the
nanoplatform for drug delivery and theranostic applications. Dynamic
light scattering (DLS) is a method of choice to measure size, dispersion,
mobility, surface charge, and concentration of exosomes [53]. Several
other standard techniques such as transmission electron microscopy
[34], scanning electron microscopy [54,55], and atomic force micro
scopy [55] are also used to examine the shape, morphology, and size of
exosomes. In addition to these mentioned techniques, Western blotting
[38], antibody based exosomal array [56,57] and flow cytometry [58,
59] are some of the methods that are used to evaluate the surface
markers of exosomes.
Upon their successful characterization, the biodistribution, phar
macokinetic, and pharmacodynamic profiles of exosomes play a signif
icant role in establishing them as a delivery platform. The
biodistribution of exosomes primarily depends on the route of admin
istration. A comprehensive study reports that milk exosomes primarily
accumulated in liver, spleen, and brain upon administration (suckling,
oral gavage, and intravenous) in mice and pigs [60]. Another study
suggests that oral administration of exosomes (DiR, a near infrared dye,
loaded) showed a uniform distribution in liver, kidney, lung, spleen,
pancreas, colon, brain, and ovaries while intravenously administered
exosomes were mostly found in the liver [55]. A bioavailability and
biodistribution study of cow milk exosomes after intravenous and oral
administration concluded that the milk exosomes were bioavailable in
mice but accumulated in liver and spleen [61]. However, only a fraction
2482
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Table 2
Commonly used techniques to separate exosomes from milk, cells, and biological fluids.
Technique

Principle

Purity

Yield

Advantage

Disadvantage

ExoQuick precipitation
Ultracentrifugation
Density gradient ultracentrifugation
Isoelectric precipitation
Size exclusion chromatography

Polymer based precipitation
Differential centrifugation
Differential centrifugation
Precipitation at isoelectric point
Porous columns filled with polymers

Low
High to low
High
Low
High

1 mL
100–500 mL
10 mL
10–20 mL
10–100 mL

Easy Method
High yield
High purity
Low cost
High yield of exosomal proteins

High cost
Time consuming
Time consuming
Low purity
Complex Method

of orally administered exosomes escaped and reached peripheral tissues
after re-packaged in the intestinal mucosa. Literature revealed that
chemical modifications of exosomes also influence the biodistribution.
For example, functionalization of exosomes with folic acid promoted the
accumulation of exosomes predominately in tumors than other organs of
lung cancer mice [62].

Since exosomes are often built up by cellular products and able to evade
phagocytosis by macrophages, which offer extended circulation time in
the body. Additionally, exosomes also prevent endo- and lyso-somal
degradation and facilitate therapeutic payloads into the cytoplasm.
Such property improves the delivery or transfection of molecules more
efficiently into the cells. Therefore, understanding of loading, release,
and stability characteristics of exosomes for drug delivery is highly
sought.
Exosomes are natural carriers filled with various biological mole
cules. These molecules often hamper the external incorporation of
therapeutic agents into exosomes. To achieve a maximum loading ca
pacity of exosomes, it is advised to remove the contents that are already
present in exosomes. However, there are no efforts or technologies exist
to offload agents from exosomes. Selective removal of these molecules
may alter the membrane integrity of exosomes. Collective literature
indicates the passive and active loading or encapsulation methods used
to load therapeutic agents into exosomes. This process is facilitated by
three specific routes: endogenous loading, exogenous loading, and
fusion methods. The endogenous method of loading represents loading
of agents during exosomal biogenesis, while the exogenous loading
method is responsible for incorporation after isolation of endosomes. On
the other hand, the fusion method leads to the generation of a composite
exosomal carrier that is combined with exosomes and other nano
liposomes. Drug loading into milk exosomes is often employed by using
the exogenous method.
The drug delivery approaches depend on the loading ability of drug
molecules into nanocarriers. Drug loading strategies into exosomes re
lies on passive (incubation) or active stimuli (sonication, electropora
tion, freeze/thaw, extrusion, or hypotonic dialysis) [72,73] (Fig. 3).
Until now, a majority of studies confirm that small chemicals, dyes,
macromolecules, and biological agents are loaded into milk exosomes
via incubation method. The following section is the comparison of
different (passive and active) methods of loading therapeutic cargos/
molecules into exosomes (Fig. 3) [74,75]. Table 3 illustrates various
methods applied to load therapeutic agents in exosomes, principles
involved in drug loading, and efficiency of loading.
Incubation: Incubation of milk exosomes or exosome secreting cells
with cargo and therapeutic molecule is the easiest process to operate and
load cargoes [55,76–78]. It represents a passive loading method. Since
exosomes have hydrophobic membranes and some hydrophilic cores,
this makes exosomes suitable for both hydrophobic and hydrophilic
cargoes. However, low loading efficiency due to physicochemical
properties of exosomes and exosomal toxicity through cargos, remain
the major challenges with incubation method.
Transfection: To load proteins, nucleic acids, and peptides onto
exosomes, transfection technique is used [79,80]. This method is
capable to load large molecules such as siRNA, miRNA, and other bio
macromolecules. The Exo-Fect method, a chemical transfection (Gene
Pulser Xcell) was implemented by transfecting siRNA into bovine exo
somes [81]. Exo-Fect successfully inserted 30% of siRNA while elec
troporation was able to introduce only <5% of siRNA. Without an active
loading method, there was almost no siRNA able to be loaded. Apart
from commercial methods (lipofection), a layer-by-layer decoration of
agents on exosomes is created for efficient delivery of siRNA [82].
However, it is a time consuming process and difficult to quantitate but it
provides stable and high loading efficiency.

4. Milk exosomes: Nature’s unique nanocarriers
Many drug molecules and biological agents are unstable in in vivo
environments which is a major concern in developing them as thera
peutic agents. To solve this issue, various nanoparticulate delivery sys
tems have been developed [63–66]. Among these nanocarriers,
polymeric nanoparticles and liposomes are two important nanocarriers
for drug delivery applications. Polymeric nanoparticles are composed of
biodegradable or biocompatible polymer(s) with stabilizers and possess
extensive abilities for entrapment, encapsulation, or conjugation of
therapeutic molecules. Whereas liposomes are spherical nanovesicles
composed of lipid bilayers of natural or synthetic phospholipids, home
to several approved therapeutics. These two nanoplatforms have the
ability to enhance the efficacy of therapeutic agents through prolonged
circulation half-life, sustained release, and targeted delivery of agents. A
number of US Food and Drug Administration approved agents based on
polymer and liposomes have been in clinical use and many more are
under various stages of clinical development. Liposomes are highly
biocompatible but less stable systemically, while polymeric nano
particles exhibit superior stability but relatively less biocompatible
material.
Polymeric nanoparticles are often synthesized by biocompatible
polymers and are known to deliver cargos in a sustained manner. One of
the biggest advantages of polymeric nanoparticles is, they provide a
variety of cargo loading including drugs, nucleic acids, proteins/anti
bodies, and peptides in order to obtain the targeted therapy [67].
Despite having these many advantages, polymeric nanoparticles have
various limitations too such as toxicity of preparation solvents and
degradation byproducts, biphasic drug release, batch to batch repro
ducibility, and large-scale production [68]. On the other hand, due to
the presence of both hydrophobic and hydrophilic sites, liposomes allow
to load a variety of hydrophobic and hydrophilic drugs and dyes [69].
The average size range for liposomes is 100–250 nm [70]. Liposomes
offer enhanced half-life, biodistribution and permeability [71]. How
ever, the use of liposomes has several limitations, mainly, their low
loading efficiency, aggregation, poor oral administration, poor stability,
toxicity, non-specific protein binding and batch to batch reproducibility
[70].
Exosomes mimic liposomal or lipid based-nanocarriers in terms of
the outer layer structure. Exosomes are “nature’s delivery systems”
which facilitate the delivery of various types of in situ encapsulated
small-to macro-molecules. Exosomes have the capability of crossing
physiological barriers including blood-brain barrier. Exosome-based
human clinical trials show encouraging outcomes in terms of biocom
patibility, feasibility, and safety. Literature reveals that exosomes can be
efficient drug delivery carrier systems due to i) superior circulation ca
pacity and bioavailability (negative zeta potential), ii) their smaller size
with deep tissue penetration capacity, iii) similarity with cellular
membranes, and iv) avoidance of degradation and quick elimination.
2483

B. Adriano et al.

Bioactive Materials 6 (2021) 2479–2490

Fig. 3. The schematic illustration of drug loading or encapsulation in exosomes. A) A simple post representation incubation strategy for passive diffusion into
exosome structures. B) An illustrative presentation of stimuli or active drug loading methods in exosomes with the help of electroporation (transfection), sonication,
freeze-thaw, extrusion, and temperature/pH gradiation.

Sonication and electroporation: Sonication (external shear force)
[83] and Electroporation (Extra electrical field) [84–86] are two ways to
create micro pores on the exosomes which allows the loading of cargo.
Both methods ensure high loading capacity but due to the intensity of
the external physical pressure and integrity of exosomes is often
compromised. These methods offer potential deformation of membrane
and are not highly efficient for hydrophobic drug(s) encapsulation.
Extrusion: Extrusion method allows drug loading by mixing exo
somes with drug(s) and the mixture is subjected to extrusion through
membranes with varied porous size (100–400 nm) [87,88]. This process
leads to disruption of membranes of exosomes which allows the drug
molecules inside the exosome compartment. The extrusion method
provides high levels of loading compared to sonication and freeze-thaw
methods. The draw-back of this method is that deformation of mem
brane occurs during the loading process.
Freeze-Thaw method: The freeze-thaw method is a straightforward
approach widely used to load drugs into exosomes. In this process,
exosomes and drugs are mixed and incubated at room temperature,

subsequently frozen (− 80 ◦ C or in liquid nitrogen or dry ice), and rethawed. The repetition of these freeze-thaw cycles enables drug encap
sulation in exosomes [72,89,90]. A moderate drug loading capacity
(lower than that of sonication or extrusion) can be achieved with this
method. Repeated freeze–thaw cycles may degrade the proteins and
alter the structural changes of EVs [54]. This method may form aggre
gations during drug loading process.
Surfactant treatment: The surfactant treatment method uses spe
cific surfactants (saponin and triton) which creates micro pores onto the
exosomal surface to load the cargo [91]. These active detergents cause
the exosome to disintegrate but show high loading capacity due to the
increased surface permeation. Moreover, surface treatment induces
pores in exosomes which leads to higher toxicity and hemolysis
concerns.
Dialysis: This method is a less commonly applied to load desired
drug cargos into exosomes [92,93]. In this method, both exosomes and
drugs are placed into dialysis tubes or bags and then dialyzed by stirring
to achieve drug-loaded exosomes. The hypotonic environment enables
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tumor/other organ homing capacity. Exosomes have proven capability
of carrying a substantial number of therapeutic agents. It obeys the
primary criteria of encapsulation of agents and intracellular delivery of
those agents by crossing cellular membranes to induce their therapeutic
actions. All these advised that exosomes may be one of the best natural
carriers for delivering drug molecules. However, milk exosomal use as a
delivery agent is still under development. This section provides sys
tematic documentation of various reports that involve milk exosomes as
a drug delivery carrier.
In general, exosomes are considered as a low immune prototype and
do not induce major side effects. The unique construction of exosomes
with lipid bilayer on the surfaces preserves their internal contents for
efficient in vivo delivery [73]. There is a huge amount of literature that
represents exosomes as nanodevices for effective delivery of therapeu
tics [96]. It is important that identifying a suitable, biocompatible, safe,
scalable, and cost-effective preparation of exosomes is warranted. Since
exosomes are composed of both hydrophilic and hydrophobic compo
nents in their structural layer, they can serve as depots for both hydro
philic and lipophilic small drug molecules. The first report by Munagala
et al. [55] proposed bovine milk exosomes for successful drug delivery
applications. This work confirms the dose and time dependent inter
nalization of milk exosomes in human lung cancer H1299 cells. It was
noticed these biological nanocarriers are bioavailable in various organs
(liver > spleen > kidneys > lung > pancreas > brain ≥ colon > ovary, in
intraperitoneal and intravenous injection of 60 mg/kg mice) and highly
safe without inducing any immunological response. Apart from these,
the encapsulated paclitaxel and withaferin A exosomes demonstrated
superior action against breast (T47D and MDA-MB-231) and lung (A549
and H1299) cancer cells. More importantly, these drug-exosomal for
mulations promoted the anticancer actions in mice bearing xenografts of
A549 lung tumors. Their subsequent investigation applied exosomes to
deliver a berry bioactive molecule, anthocyanidins. This
Anthos-exosome composition was tested in multiple (A549, H1299; PC3,
DU145; HCT116; MCF7, MDA-MB-231; Panc1, MiaPaca2; and OVCa
432; lung, prostate, colon, breast, pancreatic, and ovarian) cancer cell
lines [97]. The loading of various chemopreventive and chemothera
peutic agents (withaferin A, curcumin, paclitaxel, docetaxel) was suc
cessfully achieved by mixing in ethanol or 1:1 mixture of ethanol and
acetonitrile solution with exosome suspension. These studies also
confirm there was no effect on exosomal structure and stability identi
fied with the use of organic solvent in the loading process.
Curcumin, a natural molecule exhibiting a number of medicinal
properties. Almost all types of nanocarriers have been used to generate
curcumin nanoparticles [98,99] for improving its activity while over
coming poor pharmacokinetics, degradation, and elimination. Upon
loading curcumin in bovine milk exosomes, exosomal curcumin
exhibited enhanced stability over free curcumin and, at the same time, a
3-fold increased transport of curcumin was noticed in transepithelial
across Caco2 cell monolayer [100]. Berry anthocyanidins (natural ex
tracts) have enhanced cisplatin-induced anticancer activity against both
drug-sensitive and drug-resistant phenotype ovarian cancer cells.
Considering this, anthocyanidins were loaded into exosomes and termed
as ExoAnthos which significantly reduced the tumor growth of ovarian
cancer mouse model [101]. The same approach was extended to another
important anticancer molecule, paclitaxel [101]. This study reports that
oral exosomal drug delivery exhibited similar therapeutic efficiency as
free drug delivery through the intraperitoneal route [101].
Zhang et al. [37], reported a unique milk exosome based system with
pH and light sensitive actions by introducing doxorubicin (by hydroly
sis) and anthracene endoperoxide and chlorin e6 (EPT1 Ce6, ultrasound
sonication). This study exhibited superior anti-tumor activity of this
construct against oral squamous cell carcinomas (HSC-3, SCC-9 and
CAL-27 cell lines). This activity was noticed as: free Dox (57.28% HSC-3
cells, 48.9% SCC-9 cells and 48.1% CAL-27), Exosome with components
(71.32% HSC-3 cells, 59.9% SCC-9 and 65% CAL-27), and treatment
with 808 nm laser irradiation (48.02% HSC-3 cells, 37.43% SCC-9 and

Table 3
Descriptive information of various methods applied in therapeutic loading into
exosomes and their associated benefits and perspectives.
Therapeutic Cargo

Loading Method

Technique/
Principle

Comments

Drugs, Nucleic acids,
Proteins, and
Peptides
Proteins, Peptides, and
Nucleic acids

Incubation

Diffusion in
exosome
membrane
Gene editing

Method is easy
and simple

Drugs, Nanomaterials,
Proteins, and
Peptides

Sonication

Drugs, Nanomaterials,
Nucleic acids,
Proteins, and
Peptides
Protein and Peptides

Electroporation

Protein, Peptides, and
Nanomaterials

Surfactant
treatment

Drugs and Nucleic
acids
Nanomaterials

Dialysis

Transfection

Freeze-thaw

In situ assembly
and synthesis

External
mechanical force
to create micro
pores
External electric
force/field to
create micro
pores
Membrane fusion
with liposomes
Active agents use
to create micro
pores
pH dependent
cargo loading
Chemical
reaction

Cargo stability
and loading
efficiency
High loading
efficiency
High loading
efficiency
Moderate
loading
efficiency
High loading
efficiency
Method is easy
and simple
Exosomes
stability

the higher drug loading efficiency compared to passive incubation
method.
In situ assembly and synthesis: In situ assembly and synthesis is a
chemical reaction or deposition of drug molecules into or on the surfaces
of exosomes [94,95]. This method is only limited to growing nano
particles on the surface of exosomes. The prime advantage of this
method is no change in membrane integrity of exosome entirety.
5. Milk exosomes for theranostic applications
The milk exosomes derived from various mammals (human, cows,
goats, camels, horses, and porcine) are an abundant source compared to
cell culture-based fluids and blood plasma. Therefore, it is highly rec
ommended for developing milk exosomes as cargos for the delivery of
small molecules, biomacromolecules, nucleic acids, and or contrast
imaging agents. Many therapeutic agents are not absorbed by the
gastrointestinal tract for inducing their intended therapeutic benefit.
This resulted in the implementation of intravenous infusion of these
agents which requires multiple rounds of administration and demands
huge costs associated with hospital stay and caretaker facilities. Multiple
rounds of infusions are also a major risk factor for microbial infection in
elderly patients. Therefore, attaining a therapeutic regimen that can be
implemented at home results in greater patient compliance while
minimizing the associated costs. On the other hand, it is also advisable to
minimize the number of infusions by enhancing the therapeutic effects
using an exosomal approach. Therefore, milk exosomes may be a suit
able carrier for the delivery of drugs and imaging agents.
5.1. Drug delivery
Chemical drugs often exhibit poor water solubility or degradation
before reaching the target resulting in severe systemic side effects. The
lipid bilayer of exosomes not only improves the solubility of drugs but
also protects their chemical contents from degradation [73]. An exten
sive research effort has been paid towards developing exosomes as drug
delivery carriers. They can offer superior benefits as a delivery platform
due to their nanostructure composition with cellular membranes and
adhesive proteins. Such composition exhibits lower toxicity, unique
stability, and overcomes the blood–brain barrier issues, and improve
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36.57% CAL-27). A similar enhanced therapeutic benefit was achieved
in vivo. The synergistic photochemistry activity was noticed with NIR
contained milk exosomes in regulating tumor growth, i.e., free Dox:
~1.26 cm3 Exosomes with drug: ~0.86 cm3, exosomes with drug and
EPT1 Ce6: ~0.05 cm3 [37].
Gene silencing using siRNAs has proven to be a great promise to treat
a number of diseases. However, there is no clinically approved method
existed to deliver siRNAs. Often, oligonucleotide delivery vectors are
positively charged for successful transport into cells. This poses a threat
of toxicity issues associated with vectors. Aqil et al. [81], examined the
usefulness of bovine milk exosomes as delivery vectors for siRNA de
livery to silence specific genes of VEGF, EGFR, AKT, MAPK, and KRAS.
This investigation demonstrates that exosomes with siKRAS showed
superior internalization in A549 cells and H1299 non-small cells lung
cancer cells. Additionally, siKRAS exhibits dose dependent (0–100
pmol/mL) effect on A549 (KRASG12S mutant) but not on A1299 (KRAS
wild type) cells. Moreover, this siKRAS exosomal formulation exhibited
controlling tumor growth to only 327 ± 181 mm3 while control group
tumors grew up to 709 ± 409 mm3. This is a significant reduction (54%).

(%ID/g) of exosomes in liver (36.6 ± 7.5), spleen (31.1 ± 11.6), and
stomach (2.1 ± 0.9). In a recent study, it was demonstrated that bovine
milk exosomes can significantly alter their bioavailability and target
ability to liver and pancreas with a short-term sonication [103]. This can
be detected using a fluorescence dye-labeled exosomes. Goat milk exo
somes are biocompatible with glioma cells and showed a strong binding
potential [104]. Goat exosomes containing radionuclide 68Ga were
capable to target T7 peptide on gliomas in an orthotopic glioma mouse
model. A significant accumulation was observed under PET/CT imaging
with 4 h after injection. This suggests that exosomes can be used for
successful delivery of agents in different organs and can be extended for
therapy and non-invasive imaging technique.
6. Engineered milk exosomes
Exosomes have numerous benefits in the treatment and diagnosis of
various diseases. Therefore, engineering of the surface of exosomes with
an antibody, ligand, aptamer, and other biomacromolecules for organ or
tumor-specific delivery/binding is sought (Fig. 4) [105–107]. A simple
way to introduce such additional components on the surface of exo
somes is through hydrophobic interaction of liposomes which already
functionalized with these targeting moieties in exosome membranes
either by fusion or freeze-thaw method [108,109]. Other techniques are
to establish a i) click chemistry to modify surfaces of exosomes via 1-Eth
yl-3-(3-dimethylaminopropyl) carbodiimide -N-hydroxy succinimide
and azido group conjugation, ii) multi-valent electrostatic interactions,
i.e., positive charged moieties (cationic pullulan, lipids, and polymers)
insertion onto exosomal (negatively charged) surface membranes, and
iii) surface decoration with conjugation or self-assemblies with trans
ferrin, folic acid, hyaluronic acid, etc. [73,110–112]. Additionally, the
introduction of stimuli responsive moieties, such as temperature, pH,
extracellular matrix, redox-sensitive in exosomal membrane leads to a
unique on-demand release characteristic for exosomes [37].
However, the engineering of milk exosome investigation is limited in
the literature. Bovine milk exosomes with doxorubicin (Exo-Dox) selfassembled with DSPE-PEG2000-HA lead HA decorated Exo-Dox (HAExo-Dox, ~136 nm) [113]. HA-Exo-Dox exhibited a superior binding
with breast (MDA-MB-231 and MCF-7) and lung (HEK293 and A549)
cancer cells. This was confirmed by visual evaluation by microscopic
and quantitative flow cytometry analysis. A study demonstrated the
importance of galactose, N-acetylgalactose, mannose, fructose, and
neuraminate molecules insertion on bovine milk exosomes for improved
human intestinal cells as well as mice [114]. Among all, N-acetylga
lactose and galactose modification resulted in subsequent extensive
transport and distribution with minimal accumulation in the liver and
pancreas. Another study explored natural ligand-receptor on milk exo
somes for efficient binding of siRNAs [82]. This approach uses
lactoferrin-poly (L-lysine) mediated layer-by-layer to load siRNAs. This
surface modification enables specific internalization in Caco2 and
HepG2 cells. The colocalization capacity was up to 41.70 ± 2.39.
Together, this method is not only cost-effective but non-toxic and
chemical-free compared to commercial agents.
Exosomes comprised of theranostic agents i.e., both chemothera
peutic agent (therapy) and contrast/test agent (imaging/diagnostic
agent) are under development for cancer [80]. Along with chemother
apeutic agent(s), the addition of superparamagnetic iron oxide nano
particles (called as fexosomes for MRI imaging) and gold nanoparticles
(called nanosomes for CT/PET imaging) [81]. These agent’s inclusion in
milk exosomes can be easily adopted.

5.2. Imaging
Imaging technology is widely used to ascertain cellular localization/
distribution and tissue accumulation/biodistribution and pharmacoki
netics of molecules or agents. Efficient imaging or tracking of exosomes
in vitro describes their intra-cellular mechanism of actions and delivery
to various compartments. Besides, in vivo tracking of exosomes aids in
determining serum availability (half-life), organ-specific delivery, and
clearance of exosomes. The common imaging methods to delineate the
image characteristics of exosomes (with fluorescence, metal/metal
oxide, radiotracer labeling) includes in vitro (microscopy and flow
cytometry), in vivo and ex vivo (immunohistochemistry, luciferase ac
tivity, fluorescence/radiation/CT-SPEC imaging system). This prerequisite information directs the specific use of exosomes for proposed
diseases and if required, the exosomes can be engineered according to
the needs of applicability.
Milk exosomes are often exogenously labeled for the imaging studies.
This can be achieved by a two-step process, exosomes are manufactured
from various milk sources and then subsequently decorated with a
fluorescent membrane dye or radio tracer or other types of contrast
agent. Exosomes derived from raw cow milk labeled with NIR dye
demonstrated a superior serum availability upon oral administration
[102]. A high signal intensity was detected in the blood for 30, 60, 120,
240, and 360 min. The comparative liposome group showed a lower
intensity even at 30, 60, and 120 min whereas no signal was noticed for
240 and 360 min. This indicates that milk exosomes are a better choice
for the delivery of agents orally. These exosomes efficiently reached
major vital organs such as liver, heart, lung, kidney, and spleen and the
extent of accumulation was significant over free dye or liposomal-dye
groups. More importantly, oral exosomal delivery to the tumor site
was ~7500 IR units/protein compared to intravenous delivery ~9000
IR units/protein. However, the tumor delivery capacity is increased to
5.5-folds when these exosomes are surface tagged with iRGD peptides.
Another bovine milk exosomal-based nanosystem exhibited feasibility of
uniform in vivo distribution [37]. Through monitoring in fluorescent
imaging at different time points (1, 4, 8, 24, 48, and 72 h) advised major
signals in liver and kidney apart from the tumor. The order of accu
mulation was noticed as tumor > kidney > liver > spleen > lung ≥
heart. More importantly, these signals are higher compared to free ICG
administered group. Goat milk-derived exosomes tagged with a radio
tracer, 99mTc for evaluating pharmacokinetics and biodistribution
properties [40]. The pharmacokinetic properties of these exosomes were
evaluated by administering intravenous, intraperitoneal, and intranasal
methods. Intraperitoneal injection showed half-life of 15.97 min which
is far higher than intravenous (3.84 min) and intranasal (0.77 min)
administration. However, intravenous injections show higher retention

7. Conclusions and future directions
Exosomes are abundant nanocarriers that can offer a new chapter
and a promise for clinical applications. Milk exosomes have superior
biocompatibility, no systemic toxicity, and low adverse immune and
inflammatory responses. Exosomes are promising for use as vectors for
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Fig. 4. Different strategies explored for
engineering of exosome surface with
imaging probe (radioisotope/radio
tracer, magnetic nanoparticles, gold,
quantum dots, and labelling fluorescent
probes), targeting moieties (mono
clonal/polyclonal antibodies, aptamer,
fragmented antibodies, and other bio
macromolecules), conjugating small,
biological, macro-/bio-macromolecules
(reporter agents and other molecules),
and hybrid nanosystems. (For interpre
tation of the references to colour in this
figure legend, the reader is referred to
the Web version of this article.)

clinical application, owing to their strong biocompatibility. It is
important to consider that apart from human, goat, camel, and other
mammalian milk, bovine milk can provide a superior scalable source of
exosomes. Bovine milk exosomes are feasible to incorporate required
specific payloads of chemical, biological, and macromolecules for suc
cessful and sustained delivery. In addition, milk exosomes are found to
improve safety, bioavailability, and efficacy of therapeutic payload.
Cumulative evidence suggests that exosomes with tumor targeting li
gands enhance tumor targeted delivery and imaging technology [109,
115].
Mounting evidence confirms that milk exosomes are highly useful
nanocarriers for drug delivery but there are few challenges noticed. The
primary issue is accomplishing uniform large-scale production capa
bility, purity, and standard characterization for their effective trans
lation [116]. Although the source of exosomes is the same, the diet and
condition of the source can yield a slight district population of exosomes
with difference in shape, size, and cargo contents. The next immediate
quest is to develop rapid isolation and purification methods [117]. The
other downside of exosomes is related to their low exosomal yield, poor
encapsulation/loading efficiency of therapeutic agents. In addition, milk
exosomes always carry their exogenous biological cargo that naturally
exists inside of the exosomes. To offload such un-wanted endogenous
contents altering exosomal structural integrity is needed.
Apart from these, exosomes extend their use as delivery carriers by
avoiding unwanted accumulation or homing to the liver which cir
cumvents metabolic issues [60]. These natural carriers are capable of
long circulation time and carry therapeutic loads which can cross even
blood-brain barrier for implicating some critical therapeutic issues. It is
important to report source, variability (batch of source), the concen
tration of exosomes (number of particles, protein, and other contents), in
vitro and in vivo information for efficient clinical translation. More
attention is needed to load therapeutic agents without altering much
integral membrane stability of exosomes. A standard loading and release
characterization method needs to be followed for effective comparisons
across multiple investigations.
Overall, exosomes offer an attractive and promising therapeutic tool
for the treatment and imaging of various types of diseases. Future di
rections of exosomes research are aimed to advance multi-dimensional
use. These novel therapeutic concept-based implications can certainly
enhance the therapeutic ability of exosomes as a universal carrier. Apart
from all these, Roche has recognized the importance of milk exosomes in
the drug delivery field, a technology deal was made with PureTech to
use the exosome platform for delivering small molecules to nucleic acid/
biologics for effective oral delivery purpose [118]. Given the extent of
uniqueness, exosomes may be the solution to implement as a clinically
viable nanocarrier. It is anticipated that the potential of utilization of
these carriers as clinically relevant theranostic applications in a decade.
Milk exosomes are particularly explored as delivery carriers rather
than biological agent(s). They are in the size range of 50–200 nm which
is a good size range to follow EPR mechanism for passive targeting of
tumors or extravasation in blood vessels, while other nanosized

materials can readily cleared by the kidney (1–30 nm) or the liver or
spleen (larger particles) [59]. However, more studies such as toxicity,
immune tolerance, tissue distribution, and potency of therapeutic agents
loaded exosomes are needed to assess the clinical translation.
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[94] M. Sancho-Albero, B. Rubio-Ruiz, A.M. Pérez-López, V. Sebastián, P. MartínDuque, M. Arruebo, J. Santamaría, A. Unciti-Broceta, Cancer-derived exosomes
loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis,
Nature Catalysis 2 (10) (2019) 864–872.
[95] D. Zhang, X. Qin, T. Wu, Q. Qiao, Q. Song, Z. Zhang, Extracellular vesicles based
self-grown gold nanopopcorn for combinatorial chemo-photothermal therapy,
Biomaterials 197 (2019) 220–228.
[96] J. Dai, Y. Su, S. Zhong, L. Cong, B. Liu, J. Yang, Y. Tao, Z. He, C. Chen, Y. Jiang,
Exosomes: key players in cancer and potential therapeutic strategy, Signal
Transduction and Targeted Therapy 5 (1) (2020) 145.
[97] R. Munagala, F. Aqil, J. Jeyabalan, A.K. Agrawal, A.M. Mudd, A.H. Kyakulaga, I.
P. Singh, M.V. Vadhanam, R.C. Gupta, Exosomal formulation of anthocyanidins
against multiple cancer types, Canc. Lett. 393 (2017) 94–102.
[98] M.M. Yallapu, M. Jaggi, S.C. Chauhan, Curcumin nanomedicine: a road to cancer
therapeutics, Curr. Pharmaceut. Des. 19 (11) (2013) 1994–2010.
[99] M.M. Yallapu, P.K. Nagesh, M. Jaggi, S.C. Chauhan, Therapeutic applications of
curcumin nanoformulations, AAPS J. 17 (6) (2015) 1341–1356.
[100] M. Vashisht, P. Rani, S.K. Onteru, D. Singh, Curcumin encapsulated in milk
exosomes resists human digestion and possesses enhanced intestinal permeability
in vitro, Appl. Biochem. Biotechnol. 183 (3) (2017) 993–1007.
[101] A.K. Agrawal, F. Aqil, J. Jeyabalan, W.A. Spencer, J. Beck, B.W. Gachuki, S.
S. Alhakeem, K. Oben, R. Munagala, S. Bondada, R.C. Gupta, Milk-derived
exosomes for oral delivery of paclitaxel, Nanomed. Nanotechnol. Biol. Med. 13
(5) (2017) 1627–1636.
[102] J.L. Betker, B.M. Angle, M.W. Graner, T.J. Anchordoquy, The potential of
exosomes from cow milk for oral delivery, J. Pharmaceut. Sci. 108 (4) (2019)
1496–1505.
[103] S. Sukreet, B.V.R.E. Silva, J. Adamec, J. Cui, J. Zempleni, Sonication and shortterm incubation alter the content of bovine milk exosome cargos and exosome
bioavailability (OR26-08-19), Current Developments in Nutrition 3 (1) (2019).
[104] Z. Zhu, B. Jing, X. Lan, R. An, Goat milk-derived exosomes Endowed with
Radioactive and Targeting Properties: potential to provide PET/CT monitoring for
exosomes-based drug delivery system in gliomas therapy, J. Nucl. Med. 61 (1)
(2020) 1064.
[105] S. Salunkhe, Dheeraj, M. Basak, D. Chitkara, A. Mittal, Surface functionalization
of exosomes for target-specific delivery and in vivo imaging & tracking: strategies
and significance, J. Contr. Release 326 (2020) 599–614.
[106] Y.T. Sato, K. Umezaki, S. Sawada, S.-a. Mukai, Y. Sasaki, N. Harada, H. Shiku,
K. Akiyoshi, Engineering hybrid exosomes by membrane fusion with liposomes,
Sci. Rep. 6 (1) (2016) 21933.
[107] R. Kalluri, V.S. LeBleu, The biology and biomedical applications of exosomes 367
(6478) (2020), eaau6977.
[108] B. You, W. Xu, B. Zhang, Engineering exosomes: a new direction for anticancer
treatment, American journal of cancer research 8 (8) (2018) 1332–1342.
[109] Q. Zhan, K. Yi, H. Qi, S. Li, X. Li, Q. Wang, Y. Wang, C. Liu, M. Qiu, X. Yuan,
J. Zhao, X. Hou, C. Kang, Engineering blood exosomes for tumor-targeting
efficient gene/chemo combination therapy, Theranostics 10 (17) (2020)
7889–7905.
[110] T. Smyth, K. Petrova, N.M. Payton, I. Persaud, J.S. Redzic, M.W. Graner, P. SmithJones, T.J. Anchordoquy, Surface functionalization of exosomes using click
chemistry, Bioconjugate Chem. 25 (10) (2014) 1777–1784.
[111] M. Wang, S. Altinoglu, Y.S. Takeda, Q. Xu, Integrating protein engineering and
bioorthogonal click conjugation for extracellular vesicle modulation and
intracellular delivery, PloS One 10 (11) (2015), e0141860.
[112] S.G. Antimisiaris, S. Mourtas, A. Marazioti, Exosomes and exosome-inspired
vesicles for targeted drug delivery, Pharmaceutics 10 (4) (2018).
[113] D. Li, S. Yao, Z. Zhou, J. Shi, Z. Huang, Z. Wu, Hyaluronan decoration of milk
exosomes directs tumor-specific delivery of doxorubicin, Carbohydr. Res. 493
(2020) 108032.
[114] S. Sukreet, B.V.R.E. Silva, J. Adamec, J. Cui, J. Zempleni, Galactose and sialogalactose modifications in glycoproteins on the surface of bovine milk exosome
are essential for exosome uptake in non-bovine species (OR34-07-19), Current
Developments in Nutrition 3 (1) (2019).
[115] J. Shao, J. Zaro, Y. Shen, Advances in exosome-based drug delivery and tumor
targeting: from tissue distribution to intracellular fate, Int. J. Nanomed. 15 (2020)
9355–9371.
[116] R. van der Meel, M.H. Fens, P. Vader, W.W. van Solinge, O. Eniola-Adefeso, R.
M. Schiffelers, Extracellular vesicles as drug delivery systems: lessons from the

2489

B. Adriano et al.

Bioactive Materials 6 (2021) 2479–2490

liposome field, J. Contr. Release : official journal of the Controlled Release Society
195 (2014) 72–85.
[117] H.G. Lamparski, A. Metha-Damani, J.Y. Yao, S. Patel, D.H. Hsu, C. Ruegg, J.B. Le
Pecq, Production and characterization of clinical grade exosomes derived from
dendritic cells, J. Immunol. Methods 270 (2) (2002) 211–226.

[118] B. Hargreaves, Milk-derived Drug Delivery System Given Roche Backing, William
Reed, William Reed Business Media Ltd 2020., Broadfield Park, Crawley, 2018.

2490

